Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid  Leukemia;   Refractory High Risk Myelodysplastic Syndrome Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Quizartinib Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials